Dyadic Reports 2023 Full Year Results and Recent Company Progress
- JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the year end 2023 and highlighted recent Company progress.
- 03/28/2024
|
Dyadic Announces Change in Board and Management Leadership Roles
- JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that Michael Tarnok is stepping down as Chairman of Dyadic's board of directors (the “Board”) and that current member of the Board Patrick Lucy has been appointed to succeed him, in each case, effective immediately. Mr. Tarnok will continue to serve as a director through the end of his current term, which will end at the Company's annual meeting in June 2025, at which time he expects to retire. In addition, Dr. Barry Buckland announced that he is retiring and therefore will not stand for re-election at the Company's annual meeting in June 2024. The Board has decided not to fill the vacancy due to Dr. Buckland's retirement which will result in a reduction of the size of the Board from seven to six members. Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company.
- 03/28/2024
|
Dyadic to Attend Industry Events in April
- JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry events during the month of April 2024.
- 03/27/2024
|
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
- JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript "Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models" in Nature Communications (“Springer-Nature"), an international journal publishing peer-reviewed research in all fields of science and technology.
- 03/26/2024
|
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
- JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer and Doug Pace, Executive Vice President of Business Development will be attending the Future Food-Tech “Innovation & Investment from Farm to Fork” event March 21 – 22, 2024 at the San Francisco Marriott Marquis in California.
- 03/21/2024
|
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
- JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.
- 03/14/2024
|
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
- In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release follows:
- 03/11/2024
|
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
- JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, announced today that it entered into a securities purchase agreement on March 8, 2024, pursuant to which, the Company has sold and issued an aggregate principal amount of $6.0 million of its 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 (the “Convertible Notes”) in a private placement in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The purchasers of the Convertible Notes include immediate family members and family trusts related to Mark Emalfarb, our President and Chief Executive Officer and a member of our Board of Directors, including The Francisco Trust, an existing holder of more than 5% of the Company's outstanding common stock, (collectively, the “Purchasers”).
- 03/11/2024
|
Dyadic to Attend Industry Events in March
- JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following industry events during the month of March 2024.
- 03/01/2024
|
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
- JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV (“Rabian”), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform. This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.
- 02/28/2024
|
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
- JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR's antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.
- 02/23/2024
|
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
- JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR's antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.
- 02/21/2024
|
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
- JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila). Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.
- 02/13/2024
|
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
- JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform. Under the agreement, research and development activities will be funded by the collaborator.
- 02/06/2024
|
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
- JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following events during the month of February 2024.
- 02/01/2024
|
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
- Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health., will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.
- 01/22/2024
|
Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.
- 11/08/2023
|
Dyadic to Present at Industry Events in November
- JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of November: Cultured Meat Symposium 2023, November 2-3, 2023StarBase, Las VegasJoseph Hazelton, Chief Business Officer 8th International Vaccines Research & Development, November 6-8, 2023Hilton Baltimore BWI Airport Hotel, Linthicum Heights, MDMark Emalfarb, President, and Chief Executive Officer “Next-Gen Vaccines without the Right Platform Limit Pandemic Effectiveness C1, Protective, Rapid, High Yield, Low-Cost Global Solution” Presentation Time: Monday, November 6, 2023, 2:10 PM – 2:30 PM ET BARDA Industry Day 2023, November 13-14, 2023Grand Hyatt Washington, Washington, DCJoseph Hazelton, Chief Business Officer Vaccines Summit, November 13-15, 2023Sheraton Boston Needham Hotel, Boston, MAMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza” Presentation Time: Wednesday, November 15, 2023, 1:40 PM – 2:00 PM ET If you would like to connect with Dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic.com About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.
- 10/30/2023
|
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
- JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.
- 10/25/2023
|
Dyadic to Present at Industry and Investor Events in October
- JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic.com.
- 09/29/2023
|
Dyadic to Present at BioProcess International
- JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
- 09/12/2023
|
Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
- 08/09/2023
|
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
- JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.
- 07/26/2023
|
Dyadic International, Inc. (DYAI) Q1 2023 Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Operator Good evening, and welcome to Dyadic International's First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
- 05/10/2023
|
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
- JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.
- 04/26/2023
|
Dyadic reports 21.9% revenue rise, $12.7M in cash for full year 2022 as it rapidly advances technology
- Dyadic International Inc (NASDAQ:DYAI) posted its financial results for the year ended 2022 with revenue surging 21.9% year-over-year on the back of license agreements as it rapidly advanced its technology. For the year ended December 31, 2022, the Jupiter, Florida-based biotechnology platform company reported research and development (R&D) revenue of $2.93 million, compared to $2.40 million for the year ended December 31, 2021.
- 03/30/2023
|
Dyadic to Present at World Vaccine Congress Washington 2023
- JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.
- 03/30/2023
|
Dyadic International, Inc. (DYAI) Q4 2022 Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q4 2022 Results Conference Call March 29, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joe Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Vernon Bernardino - H.C. Wainwright Operator Good evening, and welcome to Dyadic International's Fiscal Year 2022 Financial Results Conference Call.
- 03/29/2023
|
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
- JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the year ended 2022 and host a corporate update conference call on Wednesday, March 29, 2023.
- 03/15/2023
|
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
- JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its management and business partners from VTT Technical Research Centre of Finland Ltd, will be participating at the following investor and industry events.
- 03/01/2023
|
Dyadic to Participate in Two Upcoming Investor Conferences
- JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be participating in the following two upcoming investor conferences.
- 02/02/2023
|
Dyadic International, Inc. (DYAI) Q3 2022 Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Ping Rawson – Chief Financial Officer Mark Emalfarb – President and Chief Executive Officer Joe Hazelton – Chief Business Officer Conference Call Participants John Vandermosten – Zacks SCR Lewis Titterton – Private Investor Operator Good evening and welcome to Dyadic International's Third Quarter Fiscal 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
- 11/10/2022
|
Dyadic to Present at Upcoming Industry and Investor Events in November
- JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that its management and representatives will participate in the following upcoming industry and investor events in November 2022:
- 11/07/2022
|
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
- JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the third quarter 2022 and host a corporate update conference call on Thursday, November 10, 2022.
- 10/27/2022
|
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
- JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Barcelona, Spain.
- 10/04/2022
|
Dyadic to Present at Upcoming Industry and Investor Events in September
- JUPITER, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that its management and representatives will participate in the following upcoming industry events in September 2022:
- 09/08/2022
|
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2022 Results - Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Corporate Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Vernon Bernardino - HC Wainwright Operator Good day and welcome to the Dyadic International Incorporated Second Quarter 2022 Financial Results Conference Call. Today's conference is being recorded.
- 08/10/2022
|
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
- JUPITER, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the second quarter 2022 and host a corporate update conference call on Wednesday, August 10, 2022.
- 07/27/2022
|
Dyadic to Present at 2022 Jefferies Healthcare Conference
- JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its Chief Executive Officer, Mark Emalfarb will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:00 PM ET.
- 06/02/2022
|
Dyadic to Present at H.C. Wainwright Global Investment Conference
- JUPITER, Fla., May 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the 2022 H.C. Wainwright Global Investment Conference at the Fontainebleau Miami Beach Hotel in Miami Florida. The hybrid conference will take place May 23rd - 26th, 2022. Dyadic 's President and CEO, Mark Emalfarb will be presenting on Wednesday, May 25, 2022, at 12:30 PM ET.
- 05/20/2022
|
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2022 Results - Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Robert Smith - The Center for Performance Investing Operator Good evening, and welcome to Dyadic International First Quarter Fiscal 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
- 05/12/2022
|
Dyadic International to Present at Upcoming Scientific Medical Meetings
- JUPITER, Fla., April 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its management and representatives will be presenting at the following scientific medical meetings:
- 04/04/2022
|
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2021 Results - Earnings Call Transcript
- Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2021 Results - Earnings Call Transcript
- 03/29/2022
|
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
- JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for 2021 year-end and host a corporate update conference call on Tuesday, March 29, 2022.
- 03/15/2022
|
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
- Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
- 02/15/2022
|
Dyadic International's CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
- JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company's CEO Mark Emalfarb will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis New York City February 14th -15th, and virtually through the 17th.
- 02/07/2022
|
Week 1 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge
- Two sample Breakout Stocks for Week 1 with better than 10% short-term upside potential and a Dow stock pick. This past week 1 stock beat 10% peak gains with AEHR +27.2% and METC +8.6% with Momentum Gauge® values still negative.
- 01/02/2022
|
Week 51 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An Edge
- Two sample Breakout Stocks for Week 51 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. This past week, 1 stock beat 10% peak gains in BYFC +28.2% despite high negative Momentum Gauge® values from November continuing through the week.
- 12/19/2021
|
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2021 Results - Earnings Call Transcript
- Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
- JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call on Wednesday, November 10, 2021.
- 10/27/2021
|
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
- JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company's management will be attending and presenting at the following upcoming virtual investor event:
- 09/10/2021
|
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call Transcript
- Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses
- Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100. DYAI-100 is produced using Dyadic's proprietary and patented C1-cell protein production platform.
- 08/11/2021
|
DYAI Stock Price Increases Over 54% Intraday: Why It Happened
- The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 54% during intraday trading. This is why it happened.
- 08/11/2021
|
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
- JUPITER, Fla., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, and Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ: SRNE), a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, today announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.
- 08/11/2021
|
Dyadic to Report Second Quarter 2021 Financial Results
- JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2021 and host a corporate update conference call on Thursday, August 12, 2021. Conference Call Information Date: Thursday, August 12, 2021 Time: 5:00 p.m.
- 07/29/2021
|
Best Penny Stocks to Buy Now? 4 to Watch During Earnings Season
- With earnings season in full swing, which penny stocks are investors watching right now? The post Best Penny Stocks to Buy Now?
- 07/27/2021
|
Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent
- Dyadic International Inc (NASDAQ: DYAI) stock is trading higher during the morning session on high volume after signing a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. The South African-based company is focused on discovering, developing, evaluating, and manufacturing high-quality, cost-effective vaccines for distribution primarily to African markets.
- 07/27/2021
|
DYAI Stock Increases Over 62% Intraday: Why It Happened
- The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 62% during intraday trading. This is why it happened.
- 07/27/2021
|
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa's Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
- Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries
- 07/27/2021
|
Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
- JUPITER, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs, announced today findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) project which has been published in VACCINES, a leading peer-reviewed scientific journal.
- 06/28/2021
|
Dyadic' Stock Jumps On COVID-19 Vaccine Development Pact In India
- Dyadic International Inc (NASDAQ: DYAI) has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate. The company says that the vaccine can potentially provide protection against the emerging variants and can be manufactured affordably, at an enormous scale, using Dyadic's proprietary C1-cell protein production platform.
- 05/26/2021
|
DYAI Stock Price: Over 12% Increase Pre-Market Explanation
- The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 12% pre-market. This is why it happened.
- 05/26/2021
|
Dyadic to Present at Upcoming Events
- JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the following upcoming events: Jefferies Virtual Healthcare Conference Tuesday, June 1, 2021 at 9:00 a.m. ET. Mark Emalfarb, President and CEO of Dyadic, will provide a corporate overview and update on the Company's progress in advancing its C1-Cell Protein Production Platform for use in reducing the costs of manufacturing proteins for animal and human health applications, mostly notably its COVID-19 vaccine candidate, DYAI-100, toward a first-in-human Phase 1 clinical trial later this year.
- 05/24/2021
|
Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2021 Results - Earnings Call Transcript
- Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2021 Results - Earnings Call Transcript
- 05/14/2021
|
DYAI's C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity
- Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn't simply a reproduction or tie-in to the big pharma game right now. DYAI has a new approach that isn't new-age quote-unquote “science”, but a powerful new potential […]
- 05/12/2021
|
Dyadic to Report First Quarter 2021 Financial Results
- JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2021 and host a corporate update conference call on Thursday, May 13, 2021. Conference Call Information Date: Thursday, May 13, 2021 Time: 5:00 p.m.
- 04/29/2021
|
Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”
- Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
- 04/22/2021
|
Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: NVAX)
- Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations that represent just 11% of the global population.
- 04/09/2021
|
Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript
- Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript
- 03/31/2021
|
Dyadic Reports 2020 Year End Results and Recent Company Progress
- Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates Expanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19 variant vaccines and/or boosters In parallel with DYAI-100, additional proprietary and third-party COVID-19 variant vaccine candidates are under development Developing a number of other infectious disease vaccines and antibodies internally and in conjunction with others Expanding commercial opportunities of C1 technology through eleven new and two expanded collaborations for human and animal health applications C1 selected by ZAPI (Zoonosis Anticipation Preparedness Initiative) as a vaccine manufacturing platform for more efficient production of antigens that are safe, effective, and protective Cash and investment grade securities of $29.2 million at year-end 2020 JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights. "We are very pleased with substantial progress made thus far in 2021 and over the course of 2020.
- 03/30/2021
|
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
- JUPITER, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company is expanding its partnership with South Korea's Medytox, Inc. (“Medytox”), a global biopharmaceutical company with sales in approximately 60 countries. Dyadic and Medytox will co-develop C1 manufactured COVID-19 vaccines and/or boosters, which will, if successful, be used to immunize people against two or more of the current and future COVID-19 variants. This project can provide dedicated local supply, to help combat COVID-19, in this region of the world.
- 03/22/2021
|
DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today
- Dyadic International is surging today after it announced a Covid vaccine partnership with Medytox, but that isn't the only bullish news for this small cap biotech stock. The post DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today appeared first on InvestorPlace.
- 03/22/2021
|
Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday
- Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut Shop: Odonate, an oncology-focused pharma company, said it is discontinuing the development of tesetaxel following feedback from the Food and Drug Administration in a pre-New Drug Application meeting.
- 03/22/2021
|
Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results
- JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for full year ended December 31, 2020 and host a corporate update conference call on Tuesday, March 30, 2021. Conference Call Information Date: Tuesday, March 30, 2021 Time: 5:00 p.m.
- 03/16/2021
|
Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting
- Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials
- 03/09/2021
|
Dyadic International Appoints New Board Member
- JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Patrick Lucy, to its Board of Directors, effective January 8, 2021. Mr. Lucy will serve as an independent director and a member of the Board's Science and Technology Committee.
- 01/11/2021
|
Nuveen Asset Management LLC Invests $788,000 in Dyadic International, Inc (NASDAQ:DYAI)
- Nuveen Asset Management LLC acquired a new position in shares of Dyadic International, Inc (NASDAQ:DYAI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 90,946 shares of the biotechnology company’s stock, valued at approximately $788,000. Nuveen Asset Management LLC […]
- 10/18/2020
|
Bank of Montreal Can Purchases 5,279 Shares of Dyadic International, Inc (NASDAQ:DYAI)
- Bank of Montreal Can lifted its position in Dyadic International, Inc (NASDAQ:DYAI) by 6.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,483 shares of the biotechnology company’s stock after buying an additional 5,279 shares during the quarter. Bank of Montreal […]
- 09/18/2020
|
Global Market Overview of the Industrial Enzymes Market 2020 - ResearchAndMarkets.com
|
Dyadic International (DYAI) Investor Presentation - Slideshow
- The following slide deck was published by Dyadic International, Inc. in conjunction with this event..
- 09/03/2020
|
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI) Q2 2020 Earnings Conference Call August 13, 2020 5:00 P.M.
- 08/15/2020
|
Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress
- ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the quarter ended June 30, 2020, and recent developments.
- 08/13/2020
|
MicroCap Review Magazine Summer 2020 Issue Now Available
- The Digital Issue of the Summer 2020 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.
- 08/11/2020
|
Reviewing AVITA MED LTD/S (NASDAQ:RCEL) and Dyadic International (NASDAQ:DYAI)
- Dyadic International (NASDAQ:DYAI) and AVITA MED LTD/S (NASDAQ:RCEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk. Analyst Recommendations This is a breakdown of recent ratings and price targets for Dyadic […]
- 08/09/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020
- JUPITER, FL / ACCESSWIRE / July 30, 2020 / Dyadic International, Inc.
- 07/30/2020
|
Is Dyadic International, Inc.'s (NASDAQ:DYAI) Shareholder Ownership Skewed Towards Insiders?
- A look at the shareholders of Dyadic International, Inc. (NASDAQ:DYAI) can tell us which group is most powerful...
- 07/30/2020
|
Registration for Sidoti's 2020 Fall Virtual Investor Conference is Now Open
- Our Biannual Investor Conference has become a leading forum for small-cap companies to interface with investors specifically interested in the small-cap equities.
- 07/30/2020
|
Global Baking Enzymes Market Analysis 2020-2027 with COVID-19 Impact Estimates and Profiles of 66 Competitors - ResearchAndMarkets.com
|
Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company | | IT Business Net
- JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechn
- 07/15/2020
|
Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company
- JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a new, fully-funded collaboration with another top five global pharmaceutical company. Additionally, we have been able to demonstrate the broad applications of our C1 technology, which in turn has resulted in many new wide-ranging opportunities.
- 07/15/2020
|
DYAI: Dyadic Animal Health Partners Summary
- By John Vandermosten, CFA NASDAQ:DYAI On July 8, 2020, Dyadic (NASDAQ:DYAI) announced the successful addition of two, fully funded collaborations with global animal health companies to study whether it is feasible for Dyadic’s fungal protein expression platform, C1, to produce desired therapeutic proteins. While management has not explicitly disclosed the partners, they have announced that four
- 07/10/2020
|
Dyadic Announces Two New Fully Funded Collaborations with Leading Global Animal Health Companies
- JUPITER, FL / ACCESSWIRE / July 8, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into new fully funded collaborations with two of the leading global animal health companies to demonstrate the C1 technology platform for expression and production of therapeutic proteins for companion and farm animal diseases. The regulatory pathway in animal health is much shorter with the cost of goods being a much more critical issue when compared to human vaccines and drugs.
- 07/08/2020
|
DYADIC INTERNATIONAL INC : Submission of Matters to a Vote of Security Holders (form 8-K) | MarketScreener
|
Dyadic International (NASDAQ:DYAI) Given Buy Rating at Noble Financial
- Noble Financial reaffirmed their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research note published on Monday, TipRanks reports. Noble Financial currently has a $11.00 price objective on the biotechnology company’s stock. Separately, ValuEngine raised shares of Dyadic International from a sell rating to a hold rating in a research report on Wednesday, […]
- 06/30/2020
|
Dyadic International (DYAI) Receives a Buy from Noble Financial - Markets
- Noble Financial analyst Ahu Demir reiterated a Buy rating on Dyadic International (DYAI – Research Report) today and set a
- 06/29/2020
|
Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index | | IT Business Net
- JUPITER, FL / ACCESSWIRE / June 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 ge
- 06/29/2020
|
Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index
- JUPITER, FL / ACCESSWIRE / June 29, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced today that the Company will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the US market opens on June 29, as a result of the annual Russell index reconstitution. The Russell 3000® Index measures the performance of the largest 3,000 US companies representing approximately 98% of the investable US equity market.
- 06/29/2020
|
This Revolutionary Biotech Is Shrouded in Mystery. Is It a Buy? | The Motley Fool
- This small-cap stock is developing a technology that could revolutionize biotech.
- 06/24/2020
|
The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
ACADIA Pharmaceuticals Inc...
- 06/24/2020
|
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
- 06/23/2020
|
Noble Financial Thinks Onconova Therapeutics' Stock is Going to Recover - Markets
- In a report released today, Ahu Demir from Noble Financial reiterated a Buy rating on Onconova Therapeutics (ONTX – Research
- 06/15/2020
|
Global Biocatalysis & Biocatalyst Market Trends, Forecast and Competitive Analysis to 2024 - ResearchAndMarkets.com
|
DYAI: Another Partnership, Another Step Closer to Immunizing the World
- By John Vandermosten, CFA NASDAQ:DYAI Dyadic Announces Partnership with FNLCR Dyadic International, Inc. (NASDAQ:DYAI) announced in a press release yesterday that Frederick National Laboratory will use Dyadic’s proprietary protein-expression cell line, C1, for vaccine production. The Frederick National Laboratory for Cancer Research (FNLCR) is developing several COVID-19 vaccine candidates that
- 06/11/2020
|
6 Stocks And Targets To Watch
- Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Ballard Power Systems Inc, Tesla Inc, Riot Blockchain Inc. Read Harry Boxer's latest article on Investing.com
- 06/11/2020
|
Noble Financial Keeps a Buy Rating on Dyadic International (DYAI) - Markets
- In a report released today, Ahu Demir from Noble Financial reiterated a Buy rating on Dyadic International (DYAI – Research
- 06/10/2020
|
Dyadic and Frederick National Laboratory to Develop Cell Lines for COVID-19 Vaccine Candidates Using Dyadic's C1 Gene Expression Platform
- JUPITER, FL / ACCESSWIRE / June 10, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it was selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) part of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health. "We are proud that our C1 technology has the potential to support the Vaccine Research Center COVID-19 vaccine development program by engineering innovative high yield C1 fungal cell lines to rapidly produce candidate vaccines with increased immunogenicity and attractive manufacturing properties."
- 06/10/2020
|
DYAI: Steady as She Goes
- By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT First Quarter Financial & Operational Results Dyadic International Inc. (NASDAQ: DYAI) released first quarter financial and operational results on May 14, 2020. Revenues were $0.3 million and represented research and development proceeds from partners working to develop C1. Total expenses were $2.7 million and net loss
- 05/29/2020
|
Hedge Funds Cashed Out Of Dyadic International, Inc. (DYAI)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 05/27/2020
|
Edited Transcript of DYAI earnings conference call or presentation 14-May-20 9:00pm GMT
- Q1 2020 Dyadic International Inc Earnings Call
- 05/15/2020
|
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2020 Results - Earnings Call Transcript
- Dyadic International, Inc. (NASDAQ:DYAI) Q1 2020 Earnings Conference Call May 14, 2020, 05:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - Presi
- 05/15/2020
|
Dyadic Reports 2020 First Quarter Results and Recent Developments
- Two fully funded research projects with top four animal health companies. Nonexclusive research license agreement with WuXi Biologics. Feasibility study with the University of Oslo on influenza vaccine. ...
- 05/14/2020
|
We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 05/01/2020
|
Dyadic to Report First Quarter 2020 Financial Results on Thursday, May 14, 2020
- JUPITER, FL / ACCESSWIRE / April 30, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2020 after the market close on Thursday, May 14, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. To access the replay which will expire May 28, 2020, dial 1 (877) 481-4010 (U.S. or Canada) or 1 (919) 882-2331 (International) and enter replay pass code: 34441. Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
- 04/30/2020
|
Dyadic to Present and Participate in COVID-19 Panel at the Planet MicroCap Showcase Virtual Investor Conference 2020
- JUPITER, FL / ACCESSWIRE / April 20 , 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving and applying ...
- 04/20/2020
|
DYAI: New Alliance with Chinese CDMO
- By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Full Year 2019 Financial & Operational Results Dyadic International Inc. (NASDAQ: DYAI) released full year 2019 financial and operational results on March 30, 2020. Revenues were $1.7 million and represented research and development proceeds from partners working to develop C1. Total expenses were $11.0 million and net
- 04/08/2020
|
Edited Transcript of DYAI earnings conference call or presentation 30-Mar-20 9:00pm GMT
- Q4 2019 Dyadic International Inc Earnings Call
- 03/31/2020
|
Dyadic Reports 2019 Year End Results and Recent Developments
- New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the t hird fully funded collaboration ...
- 03/30/2020
|
Dyadic International, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. (NASDAQ:DYAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at ...
- 03/30/2020
|
Dyadic Announces Nonexclusive Research License with WuXi Biologics
- JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it has entered into a nonexclusive research collaboration with WuXi Biologics, a leading global open-access biologics technology platform company and Contract Development and Manufacturing Organization (CDMO). Under the terms of the research license agreement, Dyadic will grant WuXi Biologics restricted access to its proprietary and patented C1 gene expression platform and allow WuXi Biologics to evaluate the C1 technology in a cGMP facility and to perform certain experiments to the C1 cell lines for any other internal noncommercial purpose.
- 03/30/2020
|
The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
- After starting the week ended March 28 on the backfoot, biotech stocks recovered through the week. Activity in the space remained light, although coronavirus (COVID-19) news flow continued to dominate.Here are the key catalysts that may impact biotech stocks in the unfolding week.Conferences Most conferences
- 03/29/2020
|
Dyadic International, Inc. to Present at the New York City based Investor Summit on March 25th-26th
- NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic's Chief Financial Officer Ping Rawson will be presenting at this year's New York City based Investor Summit ...
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress
- JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in the ROTH Virtual Conference on Tuesday, March 17, 2020. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.
- 03/18/2020
|
Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020
- JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the market close on Monday, March 30, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.
- 03/16/2020
|
Comparing BIO-TECHNE (NASDAQ:TECH) & Dyadic International (NASDAQ:DYAI)
- BIO-TECHNE (NASDAQ:TECH) and Dyadic International (NASDAQ:DYAI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of current ratings for BIO-TECHNE and Dyadic International, as reported by […]
- 03/15/2020
|
Neurocrine Biosciences (NASDAQ:NBIX) & Dyadic International (NASDAQ:DYAI) Head-To-Head Comparison
- Neurocrine Biosciences (NASDAQ:NBIX) and Dyadic International (NASDAQ:DYAI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Institutional & Insider Ownership 96.5% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 11.7% […]
- 03/13/2020
|
Orchard Therapeutics (NASDAQ:ORTX) versus Dyadic International (NASDAQ:DYAI) Critical Contrast
- Orchard Therapeutics (NASDAQ:ORTX) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Orchard Therapeutics and Dyadic International’s net margins, return on equity and […]
- 03/06/2020
|
Dyadic International's (NASDAQ:DYAI) Wonderful 462% Share Price Increase Shows How Capitalism Can Build Wealth
- Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
- 03/02/2020
|
Coronavirus update: Trump taps Pence to lead coronavirus response; first case in CA with no travel link
- Europe’s attempts to contain its escalating coronavirus outbreak appeared to be faltering, as Germany became the latest country to warn that it was on the verge of an epidemic.
- 02/26/2020
|
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases
- NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats. IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).
- 02/25/2020
|
Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached
- JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the 15th European Conference on Fungal Genetics ("ECFG15") demonstrated that its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP). The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd ("VTT") at the ECFG15 conference in Rome, Italy on Wednesday, February 19. "Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, Ph.D., Senior Principal Scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019," said Anne Huuskonen, VTT Senior Scientist.
- 02/24/2020
|
The Dow Rose 187 Points Because the Coronavirus Contagion Will Eventually End
- All three major indexes rose on Tuesday, recovering some ground lost in Monday’s selloff. Oil rose on coronavirus fears after hitting a three-month low on Monday, while gold retreated from a multiyear high.
- 01/28/2020
|
Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
- A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.
- 01/28/2020
|
